Steve Harr, CFO & Head, Corporate Development at Juno Therapeutics, Inc. (JUNO), sold 8,750 shares at $30.00 ($263K) on 2017-06-27, disclosed to the SEC on 2017-06-29.
Open-market sale of $262k JUNO by CFO & Head, Corporate Development. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| Filing → |
| JUNO | SELL | 2016-06-13 | $2.6M | — | Filing → |
| JUNO | SELL | 2016-03-04 | $225K | — | Filing → |
| JUNO | SELL | 2016-03-02 | $2.2M | — | Filing → |